Table 5 Incidence rates and hazard rates for subdivisions of molecular subtypes according to proliferation status and year of birth a
From: Long term trends of breast cancer incidence according to proliferation status
Molecular subtype | Proliferation marker | Born before 1929 | Born in 1929 or later | HR | 95% CI |
|---|---|---|---|---|---|
Ki-67 (%) | |||||
HER2+ | < 15 | 7.0 | 7.5 | 1.1 | (0.7–1.9) |
≥15 | 11.4 | 17.2 | 1.6 | (1.1–2.4) | |
Triple negative | < 15 | 3.7 | 2.7 | 1.1 | (0.5–2.6) |
≥15 | 8.3 | 9.7 | 1.4 | (0.9–2.3) | |
HER2+ | < 30 | 13.2 | 14.8 | 1.2 | (0.8–1.7) |
≥30 | 5.2 | 9.9 | 2.1 | (1.3–3.6) | |
Triple negative | < 30 | 6.1 | 4.3 | 1.1 | (0.6–2.2) |
≥30 | 5.8 | 8.0 | 1.5 | (0.9–2.5) | |
Mitoses/mm2 | |||||
HER2+ | ≤3.6 | 6.0 | 9.7 | 1.9 | (1.1–3.2) |
> 3.6 | 13.3 | 15.1 | 1.2 | (0.8–1.7) | |
Triple negative | ≤3.6 | 3.6 | 2.4 | 1.0 | (0.4–2.4) |
> 3.6 | 9.3 | 10.0 | 1.3 | (0.8–2.1) | |
HER2+ | < 7.7 | 13.2 | 18.8 | 1.5 | (1.0–2.1) |
≥7.7 | 6.2 | 5.9 | 1.1 | (0.6–1.9) | |
Triple negative | < 7.7 | 7.5 | 5.1 | 1.1 | (0.6–1.9) |
≥7.7 | 5.5 | 7.3 | 1.5 | (0.8–2.5) | |